Effects of Abatacept in Patients With Early Rheumatoid Arthritis

NCT02504268 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 994

Last updated 2021-06-28

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if abatacept is effective in the treatment of early rheumatoid arthritis.

Conditions

Interventions

DRUG

Abatacept

DRUG

Methotrexate

OTHER

Abatacept Placebo

OTHER

Methotrexate Placebo

Sponsors & Collaborators

Principal Investigators

  • Bristol Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-03
Primary Completion
2017-01-16
Completion
2020-03-19

Countries

  • United States
  • Argentina
  • Australia
  • Austria
  • Brazil
  • Canada
  • Chile
  • Colombia
  • Czechia
  • Finland
  • France
  • Germany
  • Hungary
  • Israel
  • Italy
  • Japan
  • Mexico
  • Monaco
  • Netherlands
  • Peru
  • Poland
  • Qatar
  • Romania
  • Russia
  • Singapore
  • South Africa
  • South Korea
  • Spain
  • Sweden
  • Taiwan
  • United Kingdom

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02504268 on ClinicalTrials.gov